[Evaluation of efficiency and safety of adding neuromultivit to basic therapy of vertebrogenic radiculopathy].
Khabirov FA, Khaibullin TI, Granatov EV · 2017 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
What does this source report?
An open randomized trial reports greater improvement in pain and disability measures when Neuromultivit was added to basic therapy.
- Population and setting
- 100 patients with L5–S1 vertebrogenic radiculopathy
- Evidence type
- Randomized trial
- Preparation
- Neuromultivit B1/B6/B12 combination; class-level context
- Source language
- Russian or indexed English translation; see original
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Open treatment and background therapy limit attribution. Short-term symptom improvement is not direct proof of nerve regeneration.
- Neuromultivit is not Binavit; formulation, route and co-interventions require separate assessment.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Indexed citation and abstract checked; complete methods and risk-of-bias appraisal pending.
Recorded source-check date: 2026-09-30. This date does not imply a completed systematic review.
Source provenance: Journal publication
Cite and trace this record
Original source: Khabirov FA, Khaibullin TI, Granatov EV. [Evaluation of efficiency and safety of adding neuromultivit to basic therapy of vertebrogenic radiculopathy]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2017.
Molekul research summary: https://molekul.io/research/bin-29171487. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry